Patient registration completed in U.S. phase 2 trial of REOLYSIN ® in combination with paclitaxel and carboplatin in head and neck cancer

Current article ratings:
Patients / public:5 (2 votes)healthcare Prof:
Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) announced today that he patient enrollment in the U.S. phase 2 clinical study (REO 015) with intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancer was completed.

"This study was carried out partially, confirm the results of our UK phase II study, that a different patient population are registered, and our current phase III study in Platinum resistant head and neck cancer, support", said Dr. Brad Thompson Chairman and CEO of Oncolytics. "This US study examined proportion of patients with prior taxane exposure than the other two studies that we conducted in this indication."

This study was a 14-patient, single arm, open-label, dose-related, non-randomised study of REOLYSIN in combination with a standard dose of paclitaxel and carboplatin intravenously given.

Patients included those with advanced or metastatic head and neck cancers, which were refractory to standard therapy, or for which no curative treatment existed. The primary objective of the phase 2 study was to measure tumor responses and duration of response, and no evidence of antitumor activity describe. The secondary goal is to the security and safety of REOLYSIN in patients with advanced or metastatic head and neck cancer in combination with paclitaxel and carboplatin administered found. Results are expected to 2011 fully be reported.

Source:
Oncolytics Biotech Inc.